Trial Profile
A 24-month, phase IV, open-label, single arm, multicenter, prospective, observational study assessing the efficacy and safety of subsequent treatment after initiation of intravitreal injection of ranibizumab 0.5 mg in diabetic macular edema patients with impaired visual acuity through individualized treatment in routine clinical practice in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms MERCURY study
- Sponsors Novartis Pharmaceuticals
- 01 Feb 2022 Primary endpoint of mean change in BCVA from baseline to 12 months has been met, according to results published in the Graefes Archive for Clinical and Experimental Ophthalmology.
- 01 Feb 2022 Status changed from recruiting to completed, according to results published in the Graefes Archive for Clinical and Experimental Ophthalmology.
- 01 Feb 2022 Interim results at 12-months (n=209) published in the Graefes Archive for Clinical and Experimental Ophthalmology